Are TNF inhibitors still the agent of choice for RA?

被引：0
|
作者：
Taylor, Peter C. [1 ]
机构：
[1] Univ Oxford, Botnar Res Ctr, Nuffield Dept Orthopaed Rheumatol & Musculoskeleta, Oxford, England
来源：
NATURE REVIEWS RHEUMATOLOGY | 2023年
关键词：
RHEUMATOID-ARTHRITIS; DOUBLE-BLIND; METHOTREXATE; COMBINATION; ADALIMUMAB;
D O I：
10.1038/s41584-023-01043
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Since entering the clinic 25 years ago, biologic TNF inhibitors have transformed the outlook for people with rheumatoid arthritis and set the standard for all other targeted therapies. Despite changes to the therapeutic landscape, TNF inhibitors look set to remain an important treatment option for the foreseeable future.
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: A single-center retrospective cohort study (KEIO-TCZ study) at week 52
    Izumi, Keisuke
    Kaneko, Yuko
    Yasuoka, Hidekata
    Seta, Noriyuki
    Kameda, Hideto
    Kuwana, Masataka
    Takeuchi, Tsutomu
    MODERN RHEUMATOLOGY, 2015, 25 (01) : 31 - 37
  • [42] Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register
    Chatzidionysiou, Katerina
    Askling, Johan
    Eriksson, Jonas
    Kristensen, Lars Erik
    van Vollenhoven, Ronald
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 (05) : 890 - 896
  • [43] New tumour necrosis factor inhibitors for rheumatoid arthritis: are there benefits from extending choice?
    Scott, David L.
    Cope, Andrew
    ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (06) : 767 - 769
  • [44] TNF Inhibitors and Myelitis: Think about it, even Lately
    Steve-Dumont, Marie
    Cohen, Mikael
    Lebrun-Frenay, Christine
    Rocher, Fanny
    THERAPIE, 2014, 69 (05): : 473 - 477
  • [45] Do RA or TNF inhibitors increase the risk of cervical neoplasia or of recurrence of previous neoplasia? A nationwide study from Sweden
    Wadstrom, Hjalmar
    Frisell, Thomas
    Sparen, Par
    Askling, Johan
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (07) : 1272 - 1278
  • [46] The Reason for Discontinuation of the First Tumor Necrosis Factor (TNF) Blocking Agent Does Not Influence the Effect of a Second TNF Blocking Agent in Patients with Rheumatoid Arthritis
    Blom, Marlies
    Kievit, Wietske
    Fransen, Jaap
    Kuper, Ina H.
    den Broeder, Alfons A.
    De Gendt, Carla M. A.
    Jansen, Tim L.
    Brus, Herman L. M.
    van de Laar, Mart A. F. J.
    van Riel, Piet L. C. M.
    JOURNAL OF RHEUMATOLOGY, 2009, 36 (10) : 2171 - 2177
  • [47] Comparative effectiveness of cycling of tumor necrosis factor-α (TNF-α) inhibitors versus switching to non-TNF biologics in rheumatoid arthritis patients with inadequate response to TNF-α inhibitor using a Bayesian approach
    Kim, Hye-Lin
    Lee, Min-Young
    Park, Sun-Young
    Park, Sun-Kyeong
    Byun, Ji-Hye
    Kwon, Sunhong
    Lee, Eui-Kyung
    ARCHIVES OF PHARMACAL RESEARCH, 2014, 37 (05) : 662 - 670
  • [48] TNF-α inhibitors and SLE
    Reactions Weekly, 2009, 1255 (1) : 3 - 3
  • [49] The Risk of Glioblastoma with TNF Inhibitors
    Guo, Michael
    Luo, Hao
    Samii, Ali
    Etminan, Mahyar
    PHARMACOTHERAPY, 2016, 36 (04): : 449 - 454
  • [50] Dose adjustments and discontinuation in TNF inhibitors treated patients: when and how. A systematic review of literature
    Ruscitti, Piero
    Sinigaglia, Luigi
    Cazzato, Massimiliano
    Grembiale, Rosa Daniela
    Triolo, Giovanni
    Lubrano, Ennio
    Montecucco, Carlomaurizio
    Giacomelli, Roberto
    RHEUMATOLOGY, 2018, 57 : 23 - 31
12345